23887-46-9

Basic information

• Product Name: Cinepazide
• Synonyms: CINEPAZIDE;1-(pyrrolidin-1-ylcarbonylmethyl)-4-(3,4,5-trimethoxycinnamoyl)piperazine;PIPERAZINE,1-[2-OXO-2-(1-PYRROLIDINYL)ETHYL]-4-[1-OXO-3-(3,4,5-TRIMETHOXYPHENYL)-2-PROPENYL];1-(1-Pyrrolidinylcarbonylmethyl)-4-[3-(3,4,5-trimethoxyphenyl)acryloyl]piperazine;1-[(1-Pyrrolidinylcarbonyl)methyl]-4-[1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]piperazine
• CAS NO: 23887-46-9
• Molecular Formula: C₂₂H₃₁N₃O₅
• Molecular Weight: 417.5
• EINECS: 245-928-9
• Mol File: 23887-46-9.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 637.8 °C at 760 mmHg
• Flash Point: 339.5 °C
• Appearance: /
• Density: 1.2 g/cm³
• Vapor Pressure: 3.65E-16mmHg at 25°C
• Refractive Index: 1.574
• PKA: 5.22±0.10(Predicted)
• CAS DataBase Reference: Cinepazide(CAS DataBase Reference)
• NIST Chemistry Reference: Cinepazide(23887-46-9)
• EPA Substance Registry System: Cinepazide(23887-46-9)

Safety Data

• Hazardous Substances Data: 23887-46-9(Hazardous Substances Data)

Usage

Description

Cinepazide is a pharmaceutical compound that is formulated as an injection for medical use. It is specifically designed to target the treatment of acute myocardial infarction, a severe condition characterized by the sudden blockage of blood flow to the heart muscle. Cinepazide's therapeutic action involves modulating the body's inflammatory response, which is a critical aspect of managing the complications and outcomes associated with myocardial infarction.

Uses

Used in Cardiology:
Cinepazide is used as an injectable treatment for acute myocardial infarction, aiming to mitigate the severity of the condition and its associated complications. The primary application reason for Cinepazide in this context is its ability to influence serum inflammatory factors, which play a significant role in the progression and management of myocardial infarction. By modulating these inflammatory factors, Cinepazide can potentially reduce the extent of tissue damage, improve patient outcomes, and support recovery following a myocardial infarction event.

World Health Organization (WHO)

Cinepazide, a vasodilating agent, was first introduced into medicine in 1974. It is used in the treatment of peripheral and cerebral vascular disorders. Following reports of blood dyscrasias, including agranulocytosis and thrombocytopenia, associated with the use of the drug, the Spanish Committee on Drug Surveillance has recommended its withdrawal. In other countries, the approved product information of preparations containing cinepazide has been amended to include a relevant warning on these adverse effects.

InChI:InChI=1/C22H31N3O5/c1-28-18-14-17(15-19(29-2)22(18)30-3)6-7-20(26)25-12-10-23(11-13-25)16-21(27)24-8-4-5-9-24/h6-7,14-15H,4-5,8-13,16H2,1-3H3/b7-6+

Upstream product

• 39890-45-4 1-[(pyrrolidine-1-carbonyl)methyl]piperazine 
• 10263-19-1 3',4',5'-trimethoxycinnamoyl chloride 

Relevant articles and documents

Benzylpiperazine derivatives. VIII. Syntheses, antiulcer and cytoprotective activities of 1-(aminocarbonylalkyl)-4-benzylpiperazine derivatives and related compounds

-